Autologous Bone Marrow-Derived Mononuclear Cell Therapy Prevents the Damage of Viable Myocardium and Improves Rat Heart Function Following Acute Anterior Myocardial Infarction

Prompt Bone Marrow-Derived Mesenchymal Stem Cell Therapy Enables Early Porcine Heart Function Recovery from Acute Myocardial Infarction

“…Consistently, previous studies have reported that stem cell therapyenhanced angiogenesis may play an essential role in improving LV function in the setting of ischemia-related organ dysfunction. 3,25,28,[30][31][32] Accordingly, our findings, in addition to reinforcing those of previous studies, 3,25,28,[30][31][32] could partially explain the notable improvement in endothelial function (ie, ET-1 level decreased in Supplemental Figure 3E, 3F) and heart function after BMDMSC transplantation.…”

“…Moreover, by day 90 after AMI procedure, not only the R EDV/BW but also the R ESV/BW was substantially lower in MI animals with BMDMSC therapy than in those MI animals without. Our results support the findings of previous stud- STEM CELL ENABLES EARLY HEART FUNCTION RECOVERY ies [1][2][3][4][5]21,25) that stem cell therapy offers benefit in preserving LV function and inhibiting LV remodeling following AMI.…”

“…BMDMSC transplantation improved heart function -role of paracrine/chemokine effects and generation of angiogenesis factors: A number of studies have previously shown that paracrine effects and enhanced production of chemokines 3,6,[28][29][30][31] and cytokines 32) played an important role in improving ischemia-related organ dysfunction. One important finding in the present study is the fact that, as compared with MI animals without treatment, the gene expressions of eNOS, VEGF, and IL-8/Gro, three indicators of paracrine/chemokine factors in both infarct and peri-infarct areas, were remarkably increased in MI animals after BMDMSC therapy.…”

“…A lthough the majority of experimental studies and clinical trials have endorsed the positive therapeutic role of stem cells (SC) in ischemia-related left ventricular (LV) dysfunction, [1][2][3][4][5] the currently available data are, surprisingly, not always consistent. [6][7][8][9] Indeed, some studies have reported that SC therapy exhibited only temporary 5,8,9) or minimal 10) effectiveness, or was even ineffective [11][12][13][14][15][16] in improving global LV ejection fraction (LVEF) in patients after acute myocardial infarction (AMI).…”

“…Thus, interpretation of the results of these experimental and clinical investigations are difficult because of multiple variables, including the differences in experimental and trial design, cell type used, timing of cell delivery, and parameters for outcome assessment. [1][2][3][4][5][6][7][8][9][10][11][12][13]17) To date, although there is still no definite explanation to account for the discrepancy in findings in the literature, [1][2][3][4][5][6][7][8][9][10][11][12][13] it is rational to believe that two factors are crucial in the success of SC therapy in improving ischemia-related LV dysfunction based on the results of previous reports, 4,5,[7][8][9][10][11][12][13] in other words, a larger number of SCs to be implanted 5,11,18) and an early timing of implantation [19][20][21] in the ischemic zone after AMI. Although small animals are frequently utilized in AMI experimentation Vol 55 No 4 STEM CELL ENABLES EARLY HEART FUNCTION RECOVERY for assessing the effect of stem cell therapy on heart function, an ...…”